Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Gains from Investment Securities (2024 - 2025)

Historic Gains from Investment Securities for Xilio Therapeutics (XLO) over the last 2 years, with Q3 2025 value amounting to $11.5 million.

  • Xilio Therapeutics' Gains from Investment Securities rose 4380.04% to $11.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.5 million, marking a year-over-year increase of 4380.04%. This contributed to the annual value of $8.3 million for FY2024, which is 970462.59% up from last year.
  • Xilio Therapeutics' Gains from Investment Securities amounted to $11.5 million in Q3 2025, which was up 4380.04% from $11.5 million recorded in Q2 2025.
  • In the past 5 years, Xilio Therapeutics' Gains from Investment Securities registered a high of $11.5 million during Q3 2025, and its lowest value of $21000.0 during Q1 2024.